Kou W, Cai H, Cui Y, Zhu J, Li S, Yang C
J Neurol. 2025; 272(2):176.
PMID: 39891751
DOI: 10.1007/s00415-025-12894-8.
Muehlberg C, Goerg S, Rullmann M, Hesse S, Sabri O, Wawrzyniak M
Brain Commun. 2024; 6(6):fcae409.
PMID: 39584157
PMC: 11582004.
DOI: 10.1093/braincomms/fcae409.
Brissenden J, Scerbak T, Albin R, Lee T
Mov Disord. 2023; 39(1):76-84.
PMID: 38062630
PMC: 10842158.
DOI: 10.1002/mds.29659.
Zeng W, Wang Y, Liu L, Wu Y, Xu Y, Zhai H
Heliyon. 2023; 9(7):e18081.
PMID: 37483764
PMC: 10362235.
DOI: 10.1016/j.heliyon.2023.e18081.
Jenner P, Falup-Pecurariu C, Leta V, Verin M, Auffret M, Bhidayasiri R
J Neural Transm (Vienna). 2023; 130(11):1337-1347.
PMID: 37210460
PMC: 10645644.
DOI: 10.1007/s00702-023-02655-0.
Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease.
Martinez-Nunez A, LeWitt P
J Parkinsons Dis. 2023; 13(4):441-451.
PMID: 37182902
PMC: 10357202.
DOI: 10.3233/JPD-230055.
Long-term levodopa ameliorates sequence effect in simple, but not complex walking in early Parkinson's disease patients.
Ohara M, Hirata K, Hallett M, Matsubayashi T, Chen Q, Kina S
Parkinsonism Relat Disord. 2023; 108:105322.
PMID: 36822140
PMC: 10082924.
DOI: 10.1016/j.parkreldis.2023.105322.
Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
LeWitt P, Liang G, Olanow C, Kieburtz K, Jimenez R, Olson K
Clin Neuropharmacol. 2023; 46(2):43-50.
PMID: 36688497
PMC: 10010692.
DOI: 10.1097/WNF.0000000000000538.
Morphologic brain network predicts levodopa responsiveness in Parkinson disease.
Xie Y, Gao C, Wu B, Peng L, Wu J, Lang L
Front Aging Neurosci. 2023; 14:990913.
PMID: 36688150
PMC: 9849367.
DOI: 10.3389/fnagi.2022.990913.
The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program.
LeWitt P, Stocchi F, Arkadir D, Caraco Y, Adar L, Perlstein I
Front Neurol. 2022; 13:1036068.
PMID: 36438968
PMC: 9686322.
DOI: 10.3389/fneur.2022.1036068.
Can Levodopa Challenge Testing Predict the Effect of Deep Brain Stimulation? One-Year Outcomes in a Chinese Cohort.
Lin W, Shi D, Wang D, Yang L, Wang Y, Jin L
Front Aging Neurosci. 2021; 13:764308.
PMID: 34744699
PMC: 8564390.
DOI: 10.3389/fnagi.2021.764308.
Biphasic (Subtherapeutic) Levodopa-Induced Respiratory Dysfunction in Parkinson Disease.
van de Wetering-van Dongen V, Espay A, Marsili L, Sturchio A, Holter S, Bloem B
Neurol Clin Pract. 2021; 11(4):e402-e406.
PMID: 34484937
PMC: 8382424.
DOI: 10.1212/CPJ.0000000000001043.
Optimizing the selection of Parkinson's disease patients for neuromodulation using the levodopa challenge test.
Kulshreshtha D, Pieterman M, Gilmore G, Jog M
J Neurol. 2021; 269(2):846-852.
PMID: 34191078
DOI: 10.1007/s00415-021-10666-8.
Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study.
Donzuso G, Sciacca G, Rascuna C, Cicero C, Mostile G, Nicoletti A
J Neurol. 2021; 268(11):4258-4264.
PMID: 33864515
PMC: 8505285.
DOI: 10.1007/s00415-021-10550-5.
Individual Magnetoencephalography Response Profiles to Short-Duration L-Dopa in Parkinson's Disease.
Pena E, Mohammad T, Almohammed F, Alotaibi T, Nahrir S, Khan S
Front Hum Neurosci. 2021; 15:640591.
PMID: 33790752
PMC: 8005574.
DOI: 10.3389/fnhum.2021.640591.
Consistency and Stability of Motor Subtype Classifications in Patients With Parkinson's Disease.
Ren J, Pan C, Li Y, Li L, Hua P, Xu L
Front Neurosci. 2021; 15:637896.
PMID: 33732106
PMC: 7957002.
DOI: 10.3389/fnins.2021.637896.
Continuous home monitoring of Parkinson's disease using inertial sensors: A systematic review.
Sica M, Tedesco S, Crowe C, Kenny L, Moore K, Timmons S
PLoS One. 2021; 16(2):e0246528.
PMID: 33539481
PMC: 7861548.
DOI: 10.1371/journal.pone.0246528.
Shedding Light on Nocturnal Movements in Parkinson's Disease: Evidence from Wearable Technologies.
Zampogna A, Manoni A, Asci F, Liguori C, Irrera F, Suppa A
Sensors (Basel). 2020; 20(18).
PMID: 32927816
PMC: 7571235.
DOI: 10.3390/s20185171.
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
Cilia R, Cereda E, Akpalu A, Sarfo F, Cham M, Laryea R
Brain. 2020; 143(8):2490-2501.
PMID: 32844196
PMC: 7566883.
DOI: 10.1093/brain/awaa181.
Levodopa challenge test: indications, protocol, and guide.
Saranza G, Lang A
J Neurol. 2020; 268(9):3135-3143.
PMID: 32333167
DOI: 10.1007/s00415-020-09810-7.